Bridging academia and industry: advancing systems biology and QSP education through AstraZeneca's collaborative partnerships.

Abstract

Collaborations between industry leaders and academia are crucial for advancing systems biology education and training. This article explores opportunities for partnerships to enhance the educational landscape and develop a workforce skilled in systems modelling, particularly for quantitative systems pharmacology (QSP) in drug development. Companies with a strong focus on innovation frequently explore collaborative ventures involving joint research, co-designed curricula, and specialized training programs. These partnerships provide students and researchers with insights into real-world applications of systems biology and QSP. We explicitly review success criteria for collaboration at MSc and PhD levels, discuss earlier pipeline considerations, and carefully balance the roles, incentives, and challenges for both academia and industry in collaborative ventures. Challenges in aligning academic and industry objectives exist, including resource allocation and intellectual property concerns. However, the importance of training skilled systems biologists for advancing drug discovery and development outweighs these challenges. The article concludes by highlighting successful industry-academia partnerships and offering recommendations for optimizing collaborations to meet the evolving needs of systems biology education and drive innovation in pharmaceutical research.